AG2R LA MONDIALE Adopts Akur8 to Challenge Its Approach to Health Insurance Pricing
29.6.2021 10:00:00 EEST | Business Wire | Press release
AG2R LA MONDIALE and Akur8 are delighted to announce their collaboration to transform AG2R LA MONDIALE's health insurance pricing process. This move underlines AG2R LA MONDIALE's desire to encourage innovation for the benefit of its policyholders. It also reinforces Akur8's relevance in the health insurance sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005016/en/
Specifically developed for insurance companies, Akur8's solution enhances their pricing process by automating risk and demand modeling, using a proprietary technology powered by transparent artificial intelligence. Akur8 enables insurers to significantly reduce modeling times, speed up time-to-market and increase predictive power of their models, while retaining absolute transparency and control.
With Akur8, AG2R LA MONDIALE is challenging its health insurance products’ pricing approach in order to offer its policyholders fairer, more transparent and more tailored prices.
"We are delighted to be opening this new chapter with AG2R LA MONDIALE. This move underlines their innovative spirit and ability to adapt constantly in order to serve their clients better, while putting digital transformation at the heart of their plans," said Samuel Falmagne, CEO of Akur8.
"This collaboration with AG2R LA MONDIALE marks a significant step forward in Akur8's continuous development. It reinforces the solution's relevance for health insurance and consolidates our presence in France," said Brune de Linares, Chief of Sales at Akur8.
"We are delighted to collaborate with Akur8. We are constantly seeking to provide better support to our policyholders, in an environment that calls for ever more agility and adaptability. This experimentation with Akur8 is a prime example of this approach. We hope that this unique, intuitive and innovative solution will provide value in the key process of pricing," said Anne-Charlotte de Raigniac, Director of actuarial services and medical approvals at AG2R LA MONDIALE.
About AG2R LA MONDIALE:
As a specialist in social and patrimonial protection in France, AG2R LA MONDIALE insures individuals, businesses and professional branches, providing health protection, protecting assets and income, guarding against accidents and preparing for retirement. The Group has over 15 million policyholders and provides day-to-day support to 500,000 businesses. With more than 11,000 employees, AG2R LA MONDIALE has a presence throughout mainland France and beyond. As a partnership with joint, cooperative governance, the Group cultivates a unique social protection model that closely combines profitability and solidarity, performance and social commitment. Every year it spends millions of euros helping vulnerable people and supporting individual and collaborative initiatives.
Stay up to date: www.ag2rlamondiale.fr / @AG2RLAMONDIALE
About Akur8
Akur8 revolutionizes insurance pricing with transparent AI. Akur8 has developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control over the models created, as required by regulators worldwide. Akur8 is the only solution on the market that reconciles the Machine Learning and Actuarial worlds.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005016/en/
Contact information
Press Contacts
For Akur8
Anne-Laure Klein
+33 (0)6 63 79 44 74
anne-laure.klein@akur8-tech.com
For AG2R LA MONDIALE
Mélissa Bourguignon
+33 (0)6 04 52 18 63
melissa.bourguignon@ag2rlamondiale.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom